DEA Marijuana Rescheduling Hearing Paused? Status and Timeline

Last updated Nov 9, 2026

If you are checking whether the DEA marijuana rescheduling hearing is paused, the short answer is yes, for now. The 11-day hearing concluded July 15, 2026, and Cannabis Business Times reports the process is on hold until at least November 5, 2026. Nothing has been decided on rescheduling all marijuana, including recreational products. A separate track is already moving: DEA has begun issuing federal registrations to state-licensed medical marijuana dispensaries under an April 23 order. This page sets out where each track stands as of November 2, 2026, and what is still open.

Is the DEA marijuana rescheduling hearing paused?

Yes. The broader rescheduling hearing ran 11 days and concluded July 15, 2026. According to Cannabis Business Times’s October 22 report, the process is on hold until at least November 5, 2026. The next formal steps are tied to that date.

Why was the hearing put on hold?

The most recent official step is a ruling by DEA’s Chief Administrative Law Judge, Derek C. Julius. On October 22, 2026, he declined to reopen the hearing for new testimony. He made that call after a September 23, 2026 report from the Government Accountability Office, which found gaps in DEA’s scheduling policies. Julius admitted the GAO report into the record and set a schedule for written briefs: briefs due October 29, and replies due November 5, 2026.

Briefs were due October 29, so that step has already come and gone. The replies are the step still ahead.

What happens after the replies are filed?

After the November 5 replies, the judge must certify the record and make a recommendation to DEA Administrator Terry Cole. That recommendation is nonbinding, so it does not settle the outcome by itself. DEA has not named a date for a final decision on broader rescheduling.

What is marijuana rescheduling, and does it make marijuana legal?

In this case, rescheduling means moving marijuana from Schedule I to Schedule III. Two separate actions are involved. The first is the April 23 order, signed by the Acting Attorney General and published April 28, 2026, which moved FDA-approved products containing marijuana, and products containing marijuana subject to a qualifying state-issued license, from Schedule I to Schedule III. The second is the broader proceeding covering all marijuana, including recreational products. That is the hearing described above.

Rescheduling does not make marijuana legal. The April order does not authorize recreational marijuana or other marijuana activity outside its scope, and marijuana not covered by the order remains Schedule I. The rule also states that registrations do not authorize manufacture, distribution, dispensing or use for non-medical purposes. MJBizDaily reports that adult-use cannabis remains Schedule I while a separate process runs, with no clear timeline. State adult-use laws are a separate question from federal scheduling. The Associated Press reports that two dozen states plus Washington, D.C. have authorized adult use, but that does not change federal scheduling. The rescheduling versus legalization guide covers the split in more depth.

Is DEA rescheduling marijuana right now?

In part. The medical track is being carried out now, with DEA issuing registrations to qualifying state-licensed medical dispensaries. The broader track is on hold. The April order was signed by the Acting Attorney General, and Treasury announced on April 23 that it planned tax guidance tied to it. The next formal step on the broader track is the November 5 replies, and DEA has not named a date for a final decision.

How do the medical dispensary registrations relate to the hearing?

They run on a different track. The registrations are issued under the April 23 order, not under the hearing. On October 30, 2026, the Justice Department announced the first federal registrations for qualifying state-licensed medical marijuana dispensaries. DOJ describes this as the first phase of putting the April order into effect under 21 U.S.C. 811(d). The initial group includes more than 900 dispensaries in Alabama, Florida, Mississippi, South Dakota, Texas, Virginia and West Virginia.

Each dispensary had to finish DEA’s pre-registration investigation before it was registered. DOJ says an applicant must operate under a state medical marijuana framework consistent with federal law and U.S. treaty obligations. A state license alone does not automatically bring a federal registration. Registered dispensaries are subject to federal requirements covering security, recordkeeping, inventory controls and other safeguards.

Manufacturer and distributor applications are still under review. That review includes facility inspections, production controls and quota determinations. DOJ says DEA will keep processing dispensary applications in phases. Businesses that applied in the initial 60-day period and whose applications are still pending may keep dealing in medical marijuana with qualified applicants and with newly registered entities.

DOJ has not named the registered businesses, so their names are not public. The Associated Press reports that the department did not immediately identify the approved businesses. Whether a particular dispensary is registered is therefore not answered by any public list at this point.

What were the April 28 to June 26, 2026 application dates?

April 28 to June 26, 2026 was the expedited, or timely, window. Under DEA’s October 30 guidance, a Timely Applicant is an entity that submitted a complete application, including the registration fee, in that window. The definition leaves out applicants that withdrew, applicants denied by a Final Order, and applicants that lack the required state medical marijuana license.

That window was the expedited route, not the only time to apply. DEA opened a new Schedule III registration portal for manufacturers, distributors and labs in October 2026, so applications did not close. Cannabis Business Times reports that DEA will not prioritize those newer applications until it has processed the timely applicants.

Who is on DEA’s timely applicant list?

Cannabis Business Times reports that DEA released a list of nearly 7,000 timely applicants on October 30, 2026. The list gives business types and states, not business names. By type, the count is:

By state, the largest counts reported are below. The other 23 adult-use states together account for nearly 2,800 timely applicants: 1,769 dispensaries, 707 manufacturers and 289 distributors.

The Minnesota figure is notable because the state’s other 300-plus dispensary licensees did not take part in the expedited process.

What does the November 29, 2026 supply chain date mean?

DEA’s October 30, 2026 guidance expects timely applicants to finish verification and set up compliant supply chains no later than November 29, 2026. Until then, the guidance sets out who a timely applicant may deal with.

Timely applicants may deal with other timely applicants and with DEA registrants. For example, a timely distributor can supply a timely dispenser and buy from a timely manufacturer. Timely applicants and registrants may not lawfully handle Schedule III medical marijuana with entities that did not apply in the window or have not applied, until those entities become registrants. The guidance warns that dealing with anyone else could be grounds for denying a timely application or revoking a registration.

Under the guidance, due diligence generally includes getting a copy of a DEA registrant’s certificate of registration from that registrant. It also includes getting a copy of the entity’s state license, verifying that the license is active, and keeping records of all due diligence. For timely applicants that are dispensers, manufacturers or distributors, the guidance points to a copy of the submission confirmation and a check of its document control number (DCN) on DEA’s Diversion Control website. The guidance describes the DCN check as due diligence that businesses do on each other. There is no public list of registered dispensaries.

The guidance also covers testing labs. DEA says it does not intend to penalize registrants and timely applicants for sending de minimis quantities to a non-DEA-registered analytical lab in the same state, in limited situations, if detailed records are kept. It does not permit receiving medical marijuana from a non-registered lab. On inventory, dispensers and distributors may keep possessing, dispensing and distributing stock acquired before the guidance, including stock from entities that do not qualify. The guidance states that it does not have the force and effect of law and is not meant to bind the public. The DEA Diversion Control guidance is the document to read for the exact wording.

What happened to the Minnesota dual-license businesses?

The Minnesota matter is the most disputed part of recent coverage, so it helps to separate the document from what people say about it. The document is an order to show cause, signed by Cheri Oz, assistant administrator of DEA’s Diversion Control Division, and sent to In-Dispensary, a Minneapolis dispensary. Marijuana Moment reports the document’s details. Some coverage calls the business “In-Store,” but its name is In-Dispensary.

Owner Mark Eide told the Minnesota Star Tribune that DEA agents delivered the order on October 30. The order cites Minnesota’s dual-purpose license, which permits both medical and non-medical dispensing, and says that license falls outside the definition of a state medical marijuana license. It also points to veterans who can self-certify, and to products it describes as synthetic marijuana, referring to hemp-derived cannabinoids. The Star Tribune notes that none of the listed reasons concerned violations of state law.

An order to show cause is not a final denial. The business may request a hearing before an administrative law judge within 30 days, or it may submit a corrective action plan. The guidance’s definition of a timely applicant leaves out withdrawn applications and applications denied by a Final Order, so a show-cause order sits at a different stage from either.

Eide said DEA told him others were getting the same document. Gillian Schauer, executive director of the Cannabis Regulators Association, said DEA sent orders to businesses in a range of states, including states that have only legalized medical cannabis, and that state regulators received no notice. No published count of these orders has been released.

Minnesota’s Office of Cannabis Management said the letter does not affect the state law that authorizes its medical and adult-use programs, and that medical cannabis remains available to patients.

Cannabis attorney Carol Moss, of Edina, said the biggest effect is that businesses in dual-market states would miss the Schedule III tax benefit even if they are not involved in recreational sales. She added that if the problem lies in state law, the owner probably has little ability to correct it. Neil Willner of Vicente LLP said DEA appears to be testing whether a whole state can be disqualified, rather than judging individual applicants.

Can adult-use businesses register under this order?

As of November 2, 2026, it is unclear. Marijuana Moment notes that state recreational programs do not issue doctors’ written certifications, so it is unclear how adult-use businesses could register even if broader rescheduling is adopted.

The rule’s certification standard is specific. A certification counts for dispensing when it is dated and signed the day it is issued, shows the user’s full name and address, and includes the name, address and state license number of the authorized practitioner who signed it. The Associated Press reports that it remains unclear what requirements DEA may impose, including on owners with criminal histories.

Why is rescheduling marijuana controversial?

People disagree, and the current coverage shows concerns from several directions. Steph Sherer of Americans for Safe Access called the registrations “a tremendous victory for patient access.” Chris Lindsey of the American Trade Association for Cannabis and Hemp said the industry is watching what operations look like now that companies are operating in this class.

Cautious observers raise practical concerns. Carol Moss says businesses in dual-market states would lose the tax benefit. Gillian Schauer lists open questions about how DEA will purchase and resell marijuana, how it will coordinate with states, and what its enforcement priorities are. The September 23 GAO report found gaps in DEA’s scheduling policies, and the Minnesota order puts a state’s dual-purpose license category in question. Owners with criminal histories face an unresolved question about what DEA may require.

What does rescheduling mean for taxes and 280E?

Treasury’s April 23, 2026 press release says Treasury and the IRS plan guidance on the federal tax effects of the final order. Section 280E generally disallows deductions and credits for a business that traffics in Schedule I or II substances. Treasury says rescheduling generally removes that bar for businesses that, because of the order, no longer traffic in those substances.

Expected guidance would confine 280E to activities tied to those substances in businesses with several activities, for example by splitting expenses. It would also start the change in the taxable year containing the order’s effective date. The final order states that, as a consequence of the rule, state licensees will no longer be subject to the 280E deduction disallowance. It also says the rule is not a determination of federal tax liability, and that qualifying state licensees should consult tax counsel. Whether Treasury and the IRS have issued the expected guidance since April is still open.

How long will marijuana rescheduling take?

There is no set date for a final decision on broader rescheduling. The steps on the record are the October 29 briefs, the November 5 replies, the judge’s certification of the record, and a nonbinding recommendation to Administrator Cole. The adult-use process has no clear timeline, according to MJBizDaily. On the medical track, DEA is processing dispensary applications in phases, manufacturer and distributor reviews are still underway, and the supply chain date for timely applicants is November 29, 2026.

Does rescheduling affect drug testing, trucking or federal employees?

This page covers the DEA scheduling process and the registrations under it. Drug testing and commercial driving are covered in the DOT drug tests and marijuana rescheduling guide. For how testing works more generally, the THC drug testing and detection page covers the detection side. Federal employment questions are not covered by the DEA steps described here, which concern scheduling and dispensary registrations.

Is Congress changing hemp rules at the same time?

That is a separate track. Vicente LLP’s analysis says H.R. 6500 moved the federal hemp total THC standard and the 0.4 milligram total THC per container limit to December 11, 2026. Public Law 119-37, signed November 12, 2025, amended the hemp definition in section 781. The hemp deadline is not part of the rescheduling hearing. For state-by-state legality of Delta-9 products, the Delta-9 state legal guide covers the hemp side.

Update: final briefs filed (November 2026)

Marijuana Moment reported on November 6, 2026 that DEA and the opposing hearing participants filed what are expected to be the final briefs on Thursday, November 5, 2026. Those briefs go to DEA Chief Administrative Law Judge Derek Julius, who will issue a recommendation to the DEA administrator on moving marijuana from Schedule I to Schedule III. Marijuana Moment’s November 9, 2026 newsletter also reported the DEA filing.

In its brief, DEA asks the judge to give the Government Accountability Office report “no weight,” saying it adds nothing new. The opponents, including the National Drug & Alcohol Screening Association, DUID Victim Voices and Kenneth Finn, argue the report shows the government’s process was flawed. The judge had admitted that report in October while denying the request to reopen the hearing for new testimony.

The next step is the judge’s recommendation to the DEA administrator. As of November 9, 2026, none had been reported with a date. The Justice Department’s October 30, 2026 release describes the broader proposed rescheduling as a separate administrative proceeding from the April 23 order.

What is still unknown as of November 2, 2026?

• Which dispensaries are registered. DOJ has not named them.
• How DEA will buy and resell marijuana, how it will coordinate with states, and what its enforcement priorities are. The Cannabis Regulators Association lists these among its open questions.
• What requirements DEA may place on owners with criminal histories. The Associated Press says that remains unclear.
• How the Minnesota show-cause matter ends, whether through a hearing or a corrective action plan.
• When the adult-use process will move. MJBizDaily reports no clear timeline.
• Whether Treasury and the IRS have issued the 280E guidance expected since April.
• When DEA will make a final decision on broader rescheduling. DEA has not named a date.

Related guides on this site

The order, deadlines and what changed are covered in marijuana rescheduling. The patient and operator side is covered in the medical marijuana schedule III patient guide. The federal marijuana law explainer sets out how these separate tracks fit together.

This content is for informational purposes only and does not constitute legal or investment advice. HealthDataConsortium.org is an analytical publication and is not affiliated with any government entity or cannabis industry organization.

Disclosure: This article may contain affiliate links. If you click a link and make a purchase, we may receive a commission at no additional cost to you. All opinions remain our own.

By HealthDataConsortium.org Research Team